Evidence receipt / belief
Published · transcript-backedSpeaker unverified: belief
6 Apr 2021 Acquired Special: "Why Now" for Digital Health (with Levels founder Josh Clemente)
“Then you—the end-user—are just going to go through whatever experience has been built. It's like your feedback, your customer experience, your process of improvement falls behind I think where any consumer mass-market consumer product would be just because there are so many conflicting incentives in there.”
— Speaker unverified
Source trail
Everything needed to verify it.
- Speaker
- Speaker unverified
- Attribution
- Not verified from this transcript
- Claim type
- belief
- Recorded
- 6 Apr 2021
- Publisher
- Acquired
Transcript context
…To your point, once you're in that, you also should have a great experience. Exactly. There's a ton of opportunity there. It's been like, you have superficial population generality happening in the digital space for the general wellness group. Once your post-diagnosis, you get more targeted, more consistent information, but the friction level is so high and the actionability of the data is just not the focus. I hate using terminology like this but it is very true. Once you're in the captured audience, you have a payer who's going to reimburse, you have a doctor who is going to draw from their list of potential treatments, and they're going to diagnose and prescribe. Then you—the end-user—are just going to go through whatever experience has been built. It's like your feedback, your customer experience, your process of improvement falls behind I think where any consumer mass-market consumer product would be just because there are so many conflicting incentives in there. You mentioned, payer for folks in the audience who are deep in the space. We're talking about insurance companies mostly, maybe employers occasionally, and the government too through Medicare or Medicaid. This is where that business model, if you’re a medical device company, if you’re a pharmaceutical company, if you're something that's been historically operating in the therapeutic space, it's a great business. This is why biotech, this is why medical device venture has been a thing for so many decades. But it's so different from the tech world where you get something, you demonstrate efficacy, you prove that to payers—all those categories over a long period of time, and then you basically just have a license to print money forever.…
Stored transcript either side of the excerpt. The highlighted words are the published quote; the surrounding text is unedited source, never generated.